United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITES EXCHANGE ACT OF 1934.

Commission File Number 000-27324

Synaptic Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)

215 College Road
Paramus, New Jersey 07652
(201) 261-1331
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, par value $0.01 per share
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provisions(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)(i)/x/	Rule 12h-3(b)(1)(i)/x/
Rule 12g-4(a)(1)(ii)/ /	Rule 12h-3(b)(1)(ii)/ /
Rule 12g-4(a)(2)(i)/ /	Rule 12h-3(b)(2)(i)/ /
Rule 12g-4(a)(2)(ii)/ /	Rule 12h-3(b)(2)(ii)/ /
	Rule 15d-6/ /

Approximate number of holders of record as of the certification or notice date: One.

        Pursuant to the requirements of the Securities Exchange Act of 1934, Synaptic Pharmaceutical Corporation has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: March 6, 2003
By:
/s/  EDMUND CAVIASCO Name: Edmund Caviasco
Title: Principal Financial Officer